The Texas Medical Center (TMC), in collaboration with the Gulf Coast Consortia for Quantitative Biomedical Sciences (GCC) and The University of Texas Medical Branch at Galveston (UTMB), was selected for a $5M grant from The Cancer Prevention and Research Institute of Texas (CPRIT) for a new cancer therapeutics program.
The Cancer Prevention and Research Institute of Texas (CPRIT) has announced the dispersal of 71 new statewide grants totaling $136 million in order to further bolster the advancement of the fight against cancer. As part of the announcement, TMC received $5 million in funding toward the development of a new accelerator specifically designed for individuals, or early-stage startups, that are focused on developing novel cancer therapeutics.
The program, called TMC ACT (Accelerating Cancer Therapeutics), will be a comprehensive nine-month program designed to enhance biotech entrepreneurship training and comprehensive drug development programs in Texas. It will simultaneously provide Texas researchers and startup companies with integrated training, resources, and mentoring in order to help advance innovative cancer therapy discoveries into clinical trials, ultimately leading to new approaches and therapies to treat and/or cure cancer patients.
In order to provide those selected for the program with the utmost in assets, guidance, and leadership, TMC ACT will amalgamate components from TMC Innovation Institute successful TMCx Medical Device and Digital Health accelerators, the Gulf Coast Consortia’s (GCC) network of Texas cancer researchers and research cores, JLABS pharmaceutical expertise, and the University of Texas’ recent entrepreneurship program into a best-in-class core resource to advance cancer cures.
Any question about the TMC ACT program can be sent to firstname.lastname@example.org